Westhovens et al. (2006), by comparison, found that infliximab plus MTX was tolerated well but that the higher dose increased risks of serious infection, with one case of lymphoma in the anti-TNF-α group and none in the MTX group [18]. Here, TNF is linked to lymphoma.